Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Small-Cap Stocks That Are On Fire Right Now

In this article, we will list the 5 Small-Cap Stocks That Are On Fire Right Now. Please visit 10 Small-Cap Stocks That Are On Fire Right Now to see the extended list and the methodology behind it.

5. Oruka Therapeutics (NASDAQ:ORKA)

Year-to-Date Performance: 149.38%

Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001, a long-acting monoclonal antibody targeting moderate-to-severe plaque psoriasis. The study met its primary endpoint, with 63.5% of patients achieving complete skin clearance (PASI 100) by Week 16. These efficacy rates are numerically higher than those of other current IL-23p19 inhibitors, placing ORKA-001 among the top-performing treatments for this condition.

The safety profile for ORKA-001 remained favorable and consistent with its drug class, with no serious treatment-emergent adverse events reported in the treated group. Most side effects were mild, with upper respiratory tract infections being the only common event observed. Crucially, updated data from earlier phases suggest the drug maintains effective concentrations for an entire year after a single dose, reinforcing the potential for once-yearly dosing, an improvement over current treatment frequencies.

Following these results, Oruka Therapeutics (NASDAQ:ORKA) plans to release longer-term follow-up data, including 52-week results for a subset of patients, in H2 2026. The company is also moving forward with its EVERLAST-B Phase 2b trial, with data expected in 2027. If successful, ORKA-001 could redefine the standard of care by offering high-level skin clearance with substantially fewer injections than existing biologics.

Oruka Therapeutics (NASDAQ:ORKA) is a biopharmaceutical company developing next-generation biologics for chronic skin and inflammatory diseases. Its lead antibody programs target plaque psoriasis and psoriatic arthritis, aiming to provide complete disease clearance with maintenance dosing as infrequent as once or twice a year.

4. Fastly Inc. (NASDAQ:FSLY)

Year-to-Date Performance: 150.79%

Fastly Inc. (NASDAQ:FSLY) is one of the small-cap stocks that are on fire right now. On April 9, Fastly and LALIGA partnered to develop a joint anti-piracy innovation project aimed at detecting and eliminating illegal live sports streams in real time. This collaboration addresses an economic challenge, as LALIGA estimates that piracy costs its clubs between $700 and $800 million annually. To combat this, Fastly has designed an intelligent detection system that uses AI and proprietary content signals to identify unauthorized broadcasts with high precision, allowing platform customers to remove infringing content quickly.

The partnership focuses on reducing the critical window of opportunity for pirates, which is essential given that recent studies show only a small fraction of illegal retransmissions are currently addressed within the first 30 minutes of an event. Unlike traditional methods like regional blocking, Fastly Inc.’s (NASDAQ:FSLY) solution is built to disable specific pirated segments while ensuring that legitimate traffic remains unaffected.

This initiative is part of a broader strategy by LALIGA, which has already seen a 60% reduction in pirated streams in Spain during the 2024/25 season through legal and technological measures. Fastly and LALIGA are now collaborating with other technology firms, publishers, and regulators to establish industry best practices and software solutions.

Fastly Inc. (NASDAQ:FSLY) operates a programmable, high-performance edge cloud platform that delivers faster, safer, and more scalable sites and apps to customers.

3. Veradermics Incorporated (NYSE:MANE)

Year-to-Date Performance: 158.15%

Veradermics Incorporated (NYSE:MANE) is one of the small-cap stocks that are on fire right now. On April 27, Veradermics announced positive topline results from its Phase 2/3 “302” clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation for male pattern hair loss. The study, which included 519 participants, met all primary and key secondary endpoints with high statistical significance.

The trial also highlighted strong patient and investigator satisfaction. ~80% to 86% of patients reported improvements in hair coverage. This consistent response across the study population suggests that VDPHL01 could offer a highly reliable and differentiated clinical profile compared to existing off-label or over-the-counter options. Safety data for VDPHL01 was equally encouraging, demonstrating a favorable tolerability profile with adverse event rates similar to those of the placebo.

The extended-release gel matrix is specifically designed to maintain steady absorption while avoiding the high peak concentrations often linked to cardiac side effects. If approved, VDPHL01 would become the first non-hormonal oral treatment for pattern hair loss cleared by the FDA in nearly 30 years, potentially addressing a significant unmet need for the 80 million men and women in the U.S. currently suffering from the condition.

Veradermics Incorporated (NYSE:MANE) develops therapies for dermatologic and aesthetic conditions.

2. MaxLinear Inc. (NASDAQ:MXL)

Year-to-Date Performance: 194.55%

MaxLinear Inc. (NASDAQ:MXL) is one of the small-cap stocks that are on fire right now. On April 23, MaxLinear reported Q1 2026 net revenue of $137.2 million, representing a 43% increase year-over-year. This growth was driven by an inflection in the company’s infrastructure business, which surged 136% compared to the prior year. On a non-GAAP basis, the company achieved a gross margin of 59.5% and diluted EPS of $0.22, a notable improvement from the loss of $0.05 per share reported in Q1 2025.

Management attributed this performance to accelerating momentum in optical data center connectivity, particularly for AI-driven hyperscale platforms. Looking ahead, the company provided an optimistic outlook for Q2 2026, projecting net revenue to rise to between $160 and $170 million, marking what management describes as a step-function increase in their optical business.

Additionally, MaxLinear Inc. (NASDAQ:MXL) announced an amendment to its credit agreement with Wells Fargo, extending the maturity of its revolving credit facility to March 2028. The amendment also increased the available facility amount by $30 million, bringing the total capacity to $130 million. While the facility remains undrawn, the extension and increased capacity provide the company with enhanced financial flexibility as it enters what it describes as a multi-year growth phase.

MaxLinear Inc. (NASDAQ:MXL) provides communications systems-on-chip solutions in the US, Asia, Europe, and internationally. It serves electronics distributors, module makers, OEMs, and original design manufacturers.

1. Aehr Test Systems Inc. (NASDAQ:AEHR)

Year-to-Date Performance: 339.20%

Aehr Test Systems Inc. (NASDAQ:AEHR) is one of the small-cap stocks that are on fire right now. On April 16, Aehr Test Systems secured a record $41 million follow-on production order from its primary hyperscale customer, marking the largest single contract in the company’s history. The order is for Aehr’s Sonoma high-power package-level burn-in/PLBI systems, modules, and sockets, which are used to test custom AI processor ASICs for data center training and inference workloads. Deliveries are scheduled to begin in the company’s fiscal year 2027, starting in late June this year.

This latest order brings Aehr’s total bookings for the second half of the fiscal year to over $92 million, significantly exceeding previous management guidance of $60 million to $80 million. CEO Gayn Erickson noted that the Sonoma platform is gaining significant traction as hyperscale providers shift toward custom-designed AI accelerators.

Beyond current production, the lead customer has also placed initial orders for systems to support a next-gen, higher-power AI accelerator expected to enter volume production later this year. To accommodate this surging demand and a growing pipeline across sectors like silicon photonics and power semiconductors (SiC and GaN), Aehr Test Systems Inc. (NASDAQ:AEHR) expanded its Fremont, California, facility and upgraded its contract manufacturing capacity.

Aehr Test Systems Inc. (NASDAQ:AEHR) designs, markets, manufactures, and sells test and burn-in equipment used in the semiconductor industry. The company’s products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures.

While we acknowledge the potential of AEHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AEHR and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.